Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia

Predictive value of FCGR3A genotype on response to rituximab induction and maintenance therapy (MT) in follicular non-Hodgkin's lymphoma (NHL).

(2017) K. A. Pierz et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of the CD20-directed monoclonal antibody GA101 relative to rituximab in Waldenstrom's macroglobulinemia (WM), and applicability to patients expressing FcγRIIIA-158 F/F.

(2017) G. Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial

(2010) P. Moreau et al.   BLOOD

Rituximab and Subcutaneous 2-Chloro-2′-Deoxyadenosine Combination Treatment for Patients With Waldenström Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter Study

(2010) Daniele Laszlo et al.   JOURNAL OF CLINICAL ONCOLOGY

High-Dose Therapy and Autologous Stem-Cell Transplantation in Waldenström Macroglobulinemia: The Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

(2010) Charalampia Kyriakou et al.   JOURNAL OF CLINICAL ONCOLOGY

International prognostic scoring system for Waldenstrom macroglobulinemia

(2009) P. Morel et al.   BLOOD

How I treat Waldenstrom macroglobulinemia

(2009) S. P. Treon   BLOOD

CR represents an early index of potential long survival in multiple myeloma

(2009) M Wang et al.   BONE MARROW TRANSPLANTATION

Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial

(2009) Morie A. Gertz et al.   BRITISH JOURNAL OF HAEMATOLOGY

Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180

(2009) Steven P. Treon et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab

(2009) Wen-Kai Weng et al.   LEUKEMIA & LYMPHOMA

Thalidomide and rituximab in Waldenstrom macroglobulinemia

(2008) S. P. Treon et al.   BLOOD

Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003

(2008) M. V. Dhodapkar et al.   BLOOD

Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia

(2008) S. P. Treon et al.   BLOOD

FcγRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients

(2008) Márcia Paiva et al.   CANCER GENETICS AND CYTOGENETICS

Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia

(2008) S. P. Treon et al.   CLINICAL CANCER RESEARCH

The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens

(2008) M. A. Dimopoulos et al.   HAEMATOLOGICA

Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

(2008) Franck Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Evidence for Linkage Disequilibrium Between FcγRIIIa-V158F and FcγRIIa-H131R Polymorphisms in White Patients, and for an FcγRIIIa-Restricted Influence on the Response to Therapeutic Antibodies

(2008) Julien Lejeune et al.   JOURNAL OF CLINICAL ONCOLOGY

Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

(2008) Juan José Lahuerta et al.   JOURNAL OF CLINICAL ONCOLOGY

Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's Macroglobulinemia

(2008) Meletios Athanasios Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY